The prognosis and natural history of primary biliary cirrhosis (PBC) has improved, and the clinical end-point for PBC needs to be discovered. We aimed to identify surrogate markers for predicting long-term prognosis in patients with PBC.
INTRODUCTION

P
RIMARY BILIARY CIRRHOSIS (PBC) is a chronic, destructive cholangitis associated with interlobular bile duct loss (BDL), cholestasis, and progressive fibrosis.
1 Primary biliary cirrhosis is histologically characterized by chronic non-suppurative destructive cholangitis and small intrahepatic bile duct destruction, causing biliary cholestasis that may ultimately cause an unfavorable biochemical response 2 and progress to end-stage liver disease requiring liver transplantation. 3 Ursodeoxycholic acid (UDCA) is the only Food and Drug Administration-approved therapy for PBC. Clinical studies have indicated that a biochemical response to UDCA after 1-2 years of treatment can predict clinical outcomes, including cirrhosis development time, transplantation-free survival, and liver-related mortality in patients with PBC. 2, [4] [5] [6] [7] Approximately 80% of PBC cases are diagnosed during the early and symptomatic phases of the disease based on clinical examinations or serological tests carried out for other reasons. Given the gradually progressive nature of PBC, UDCA treatment efficacy should be assessed at least 1 year after therapy initiation. Alternatively, Angulo et al. and Azemoto et al. reported the prognostic impact of alkaline phosphatase (ALP) 8 and γ-glutamyl transpeptidase (γ-GTP) 9 ,10 levels measured 6 months after UCDA therapy initiation.
Patients with inadequate biochemical responses to UCDA therapy have a high risk of serious adverse events, including liver transplantation and death from liverrelated causes. Such serious adverse events may, however, not be acceptable as valid primary study end-points because the disease was diagnosed at an earlier stage and patient survival improved with earlier UDCA treatment. No biological markers have been scientifically validated as surrogate end-points for evaluating treatment responses in PBC. Accordingly, there is an urgent clinical need for surrogate markers with utility in reliable risk stratification and outcome prediction for patients with PBC treated with UDCA.
Liver histology plays a pivotal role in predicting the prognosis of patients with PBC 11 despite heterogeneous distribution of inflammation and fibrosis of portal tracts. The proposed staging system by Nakanuma et al. is useful in separately assessing the degree of liver fibrosis and BDL for the histological staging of PBC. [12] [13] [14] The aims of the present study were to identify biochemical biomarkers with utility in predicting the prognosis of patients with PBC, to identify factors for distinguishing UDCA responders from non-responders, and to determine the utility of histologic staging based on Scheuer and Nakanuma classifications in predicting survival free of liver-related death in patients with PBC.
METHODS
Patient group
A RETROSPECTIVE REVIEW of medical records was carried out for patients with serologically and histologically confirmed PBC at Nara Medical University (Kashihara, Japan) between January 1989 and December 2012. Diagnoses were based on the Japanese version of the clinical practice guidelines for PBC, which was developed in 2012 by the Intractable Hepatobiliary Disease Study Group, with the support of the Ministry of Health, Labor and Welfare of Japan. 15 A total of 241 patients met at least two of the following three criteria: (i) a sustained elevation of serum cholestasis ALP levels for >6 months; (ii) anti-mitochondrial antibody (AMA)/ AMA subtype M2 (AMA-M2) positivity; and (iii) bile duct lesions typical of PBC seen on liver histology. Patients were treated with UDCA at a daily dose of 13-15 mg/kg/day. Bezafibrate was added in cases where the UDCA efficacy was limited after 1 year. Exclusion criteria were: (i) autoimmune overlap syndrome; 16 (ii) the use of immunosuppressive agents; (iii) clinical findings suggestive of concomitant liver diseases, including chronic hepatitis B, hepatitis C virus, and alcoholic liver disease; and (iv) a <1-year follow-up.
Clinical characteristics of patients with PBC
Age, gender, body mass index, and biochemical indices were recorded at baseline. Patients were categorized as "asymptomatic" if PBC was diagnosed by incidental findings of elevated serum ALP levels and the presence of serum AMA (titer ≥1:40) during the course of an unrelated illness. Patients were characterized as "symptomatic" if they presented with complaints of jaundice, pruritus, and/or symptoms of portal hypertension. The following laboratory parameters were measured prior to treatment and at 1 and 2 years after UDCA therapy initiation: platelet count, albumin, aspartate aminotransferase (AST), alanine aminotransferase, ALP, γ-GTP, total bilirubin, immunoglobulin M, and AMA and AMA-M2. Patients were classified into two groups, UDCA responders and UDCA nonresponders, according to the biochemical responses as defined by a reduction of ≥69% in γ-GTP from the pretreatment or normal levels after 1 year of UDCA treatment. Our definition of UDCA response was determined according to a discriminatory power to identify biological markers for predicting clinical outcome in PBC (a reduction in ALP or γ-GTP levels at 1 and 2 years after UDCA treatment initiation) using receiver-operating characteristics analysis ( Table 1) .
Definition of biochemical response and end-point
We compared six different definitions of biochemical response to UDCA after treatment: (i) our proposed definition, ≤69% decrease in γ-GTP levels from baseline after 1 year of UDCA treatment; (ii) the Barcelona definition, 4 a decrease of ≥40% in ALP from pretreatment or normal ALP levels after 1 year of treatment; (iii) the Paris-I definition, 5 ALP ≤3 times the upper limit of normal (ULN), AST ≤2 times the ULN, and bilirubin ≤1 times the ULN after 1 year of treatment; (iv) the Paris-II definition, 6 ALP and AST levels ≤1.5 times the ULN with normal Liver fibrosis predicts prognosis in PBC E179 Hepatology Research 2017; 47: E178-E186 bilirubin levels after 1 year of treatment; (v) the Rotterdam definition, 7 normal bilirubin and albumin levels after 1 year of treatment when one or both parameters were abnormal prior to treatment, or normal bilirubin or albumin levels after treatment when both were abnormal at study initiation; and (vi) the Toronto definition, 2 ALP ≤1.67 times the UNL after 2 years of treatment. The primary end-point was liver-related mortality. Patients who died of liver-unrelated causes were censored at the time of death.
Histological evaluation of liver specimens according to Scheuer and Nakanuma staging systems Biopsy specimens were processed according to routine protocols. Tissue sections were stained with hematoxylin-eosin and Azan Mallory, followed by evaluations for Scheuer 17, 18 and Nakanuma classifications. [12] [13] [14] 19 According to the Scheuer staging system, patients were classified into four stages: stages 1 and 2, early disease; and stages 3 and 4, advanced disease. Subsequently, the staging was re-evaluated for BDL and fibrosis, according to the Nakanuma classification. Bile duct loss and fibrosis were individually scored, with a total score calculated by adding the fibrosis and BDL scores (range for both scores, 0-3). A total score of 0 was classified as stage 1 (no or minimal disease progression), 1 or 2 as stage 2 (mild disease progression), 3 or 4 as stage 3 (moderate disease progression), and 5 or 6 as stage 4 (advanced disease progression). All liver specimens contained at least 15 portal tracts, including 11 complete portal triads, that is, islands of connective tissue containing portal vein and hepatic artery branches that supply blood to sinusoids and bile ducts, as confirmed by hematoxylin-eosin staining. 20 To validate histological characteristics of PBC, all cases were independently reviewed by two pathologists. Discrepancies in interpretation were discussed until consensus was achieved.
Statistical analyses
All statistical analyses were carried out using SPSS 15.0 software (SPSS, Chicago, IL, USA) and GraphPad Prism version 6.04 (GraphPad Software, Inc., La Jolla, CA, USA) for Windows. Student's t-test or one-way ANOVA followed by Bonferroni's multiple-comparison analysis were carried out for all comparisons. Survival analyses were carried out according to the Kaplan-Meier method. The log-rank test was used to compare survival distributions between two or more groups. All tests were two-tailed, with P < 0.05 considered statistically significant.
RESULTS
Clinical characteristics of patients
A MONG THE 241 patients with PBC enrolled during the study period, 122 patients were histologically confirmed as having PBC and 16 patients were excluded due to missing biochemical data, including γ-GTP values (Fig. 1 ). Demographic and baseline characteristics for the remaining 106 patients are shown in Table 2 . Among these 106 patients, 95 (89.6%) were females with a median age of 56.8 ± 8.7 years at histological diagnosis. At the time of diagnosis, 61 (57.5%) patients were characterized as symptomatic. Of 106 patients, 82 (77.4%) were at an early Scheuer histological stage and 63 (59.4%) were at an early Nakanuma histological stage. The mean observation period was 9.1 ± 5.2 years (range, 1.0-22.3 years). A total of 17 patients died during the study period, including 10 patients from hepatic disease (liver failure [n = 6], including post-liver transplantation [n = 3], and hepatocellular carcinoma [n = 4]). The remaining 7 patients, who died of non-hepatic disease (pneumonia, n = 2; non-hepatic cancer, n = 5), were censored. Figure 1 Schematic flow chart of the present study design. A retrospective review of medical records was undertaken for 241 patients with primary biliary cirrhosis (PBC). A total of 106 patients met the inclusion criteria and were divided into two groups: ursodeoxycholic acid (UDCA) responders, with a normal γ-glutamyl transpeptidase (γ-GTP) level or a decrease in γ-GTP levels of ≥69% from above the upper limit of normal (ULN) after 1 year of UDCA treatment (n = 53), and non-responders, with increased γ-GTP levels or a decrease in γ-GTP levels of <69% from above the ULN after treatment (n = 53).
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Comparisons of outcomes among the various biochemical response criteria
We analyzed the data on 106 patients with PBC including a total of 17 patients who died during the study period, comprising 10 patients who died of hepatic disease and 7 patients who died of non-hepatic disease, treated as censored cases. A total of 53 patients treated with UDCA and who achieved >69% decrease in γ-GTP levels from baseline after 1 year of UDCA treatment were defined as UDCA responders. The remaining 53 patients with a reduction in γ-GTP <69% were defined as UDCA non-responders. Long-term survival was compared between the two groups.
The findings of the present study revealed a disease-specific survival rate among UDCA responders of 100%, whereas the survival rate of UDCA non-responders was significantly lower at 71.5% (P < 0.01; Fig. 2 ), indicating that UDCA non-responders were at a high risk of developing end-stage disease and were eligible for benefits from additional therapy. Biochemical responses to UDCA were compared between patients who met the inclusion criteria for the Barcelona (n = 84), Paris-I (n = 106), Paris-II (n = 106), Rotterdam (n = 106), and Toronto definitions (n = 106). For the Barcelona criteria, 22 patients were not included as their ALP activity had been estimated using different assay techniques in our laboratory. All five definitions of biochemical response to UDCA, except for the Barcelona criteria, were able to differentiate responders from nonresponders with respect to survival free of liver-related death (P = 0.42, P < 0.0001, P < 0.0001, P < 0.0001, and P = 0.0013, respectively; Fig. 3 ). In agreement with our proposed definition, the long-term outcomes of responders according to the Paris-II criteria were 100%. The Paris II criteria could detect more UDCA responders than our proposed criteria for selecting patients in whom UDCA monotherapy can be safely continued (P < 0.01).
Factors discriminating between UDCA responders and UDCA non-responders No significant differences in baseline clinical or laboratory data were observed between the groups, with the exception of pathologic stage ( Table 3 ). The age, 21 gender, 21 Scheuer histological stage, 5 and clinical phenotype 9 of patients have been shown to be independent factors in differentiating between UDCA responders and non-responders. Univariate and multivariate logistic regression analyses Figure 2 Biochemical response to ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis. The survival rate of UDCA responders was 100% and was significantly higher than that of UDCA non-responders, with a long-term survival rate of 71.5% (P < 0.01).
Liver fibrosis predicts prognosis in PBC E181 Hepatology Research 2017; 47: E178-E186 revealed that the Scheuer histological stage was the single most decisive factor for explaining the differences between the two groups (Table 4) .
Histologic analysis of liver specimens based on Scheuer and Nakanuma histological staging systems
The histological examination of liver biopsy tissue was carried out in 106 patients according to both Scheuer and Nakanuma systems. The number of cases stratified as stage 1, 2, 3, or 4 according to the Scheuer system was 36, 46, 22 and 2, respectively. The distribution of cases in stage 1, 2, 3, or 4 according to the Nakanuma system was 7, 56, 36, and 7, respectively, with stage 2 being the most frequently observed (ig. Fig. 4a ). In corroboration with the findings of a previous report, 12 the number of cases in stage 1 was substantially lower than that in other stages, according to the Nakanuma system compared with the Scheuer system. A total of 106 patients were categorized into four classes according to fibrosis and BDL scores. The number of cases with fibrosis scores of 0, 1, 2, or 3 was 26, 59, 17, and 4, respectively, with a fibrosis score of 1 being most frequently observed (Fig. 4b) . The distribution of BDL scores of 0, 1, 2, and 3 was 9, 43, 47, and 7, respectively, with approximately 85% cases found to have BDL scores of 1 or 2 (Fig. 4c) . A comparison of the distribution of the 106 specimens classified according to both systems is shown in Figure 4(d) . Among the 25 cases classed as stage 1 according to the Scheuer system, eight cases with no fibrosis (score 0) and mild BDL (score 1), two cases with no fibrosis (score 0) and moderate BDL (score 2), one case with mild fibrosis (score 1) and no BDL (score 0), and 14 cases with mild fibrosis (score 1) and mild BDL (score 1) were classified as Nakanuma stage 2 (total stage score of 1 or 2). This finding is likely attributable to the presence of at least one histologic feature, including fibrosis and BDL, in cases classified as Scheuer stage 1. Of the 36 cases classified as Scheuer stage 1, 6 and 5 cases were reclassified as stage 1 and stage 3 of the Nakanuma system, respectively. E182 Namisaki et al.
were reclassified as Nakanuma stage 4, and were characterized by moderate fibrosis (score 2) and severe BDL (score 3), which is not considered to be cirrhosis, or moderate fibrosis (score 3) and moderate BDL (score 2), which is considered to indicate cirrhosis.
Prognostic significance of Scheuer and Nakanuma histological stages in PBC
The overall survival of the 106 patients with PBC was stratified by pathological stage according to Scheuer and Nakanuma classifications. Patient prognosis worsened with increased histological stage according to both Scheuer and Nakanuma systems. A significant difference in survival rate was observed between Scheuer stage 1 and stage 3, Scheuer stage 1 and stage 4, and between Nakanuma stage 1 and stage 4 (P < 0.05, P < 0.01, and P < 0.01, respectively; Fig. 5a,b) . We next evaluated the survival rate of patients with PBC, according to fibrosis and BDL scores determining Nakanuma stage. A significant difference in the survival rate was observed between fibrosis scores of 0 and 2 or 3 (P < 0.05 and P < 0.001, respectively; Fig. 5c ) and between BDL scores of 0 and 3 ( Fig. 5d ; P < 0.05). These findings indicate that the long-term outcome of patients with PBC is predicted by Scheuer stage 3 and Nakanuma fibrosis score 2, which indicate significant portal liver fibrosis; this might progress to a final stage or score indicating severe damage.
DISCUSSION
U RSODEOXYCHOLIC ACID IS an established and accepted therapy for PBC; however, UDCA is not universally used, and the prognosis of patients with suboptimal responses to UDCA treatment is markedly unfavorable.
2,4-9,22,23 Biochemical parameters evaluated P-values represent comparisons between responders and non-responders. BMI, body mass index; n.s., not significant. Liver fibrosis predicts prognosis in PBC E183 Hepatology Research 2017; 47: E178-E186 after 1 or 2 years of UDCA treatment are used to identify patients most likely to benefit from alternative treatments. 2, [4] [5] [6] [7] The accurate risk stratification of patients treated with UDCA is a prerequisite for identifying patients who may benefit from an additional second therapy and those at high risk of developing liver cirrhosis. To the best of our knowledge, this is the first study to report that liver fibrosis has greater utility in predicting long-term prognosis than BDL. The findings of this study show that a decrease in γ-GTP levels from pretreatment levels at 1 year after the commencement of UDCA therapy can be used for identifying patients who are initially treated with UDCA alone and are able to achieve and maintain biochemical remission.
Azemoto et al. 9 reported that patients with ≥70% reductions in serum γ-GTP levels after 6 months of UDCA treatment, defined as UDCA responders, had a better prognosis than non-responders, defined as patients with a <70% reduction in serum γ-GTP levels, although no significant difference in survival was observed between UDCA responders and non-responders after 6 months of UDCA treatment (data not shown). This discrepancy may be attributable to the fact that 45 of 106 (42.5%) patients were symptomatic and presented with advanced disease requiring UDCA treatment for longer durations to decrease γ-GTP levels than asymptomatic patients in the present study. Furthermore, two biochemical definitions have been proposed for more precise prediction of long-term outcomes in patients with PBC compared with that using previously reported criteria based on laboratory values after 1 year of UDCA therapy.
3,24 However, we must be aware that these scoring systems do not fulfill the requirements for the highest level of evidence, and further validation of potential surrogate markers is required. Primary biliary cirrhosis is a pattern of histological injury, substantially characterized by paucity of interlobular bile ducts, followed by progressive liver fibrosis with portal tract expansion, which ultimately leads to cirrhosis. 25 Multivariate analysis showed that Scheuer's histological staging was the only factor that was able to distinguish UDCA responders from UDCA non-responders. Accordingly, histological examination of liver biopsy tissues was also carried out on 106 patients according to Nakanuma system, characterized by two parameters (liver fibrosis and BDL). Given that cirrhosis is an end-stage liver disease and patients with cirrhosis generally have a poor prognosis, the long-term outcome of patients with PBC was predicted only by Scheuer stage 3 and Nakanuma fibrosis score 2, which together were referred to as significant portal-bridging fibrosis. The prognosis of patients with PBC appears to be dictated by the presence and extent of fibrosis in liver biopsy findings. 26 The long-term outcome of patients with PBC could also be independently predicted by histological features, including fibrosis. 5 In contrast, Kumagi et al. revealed that the baseline severity of BDL is associated with histological progression as well as biochemical response to UDCA. 27 Canals of Hering loss reportedly reflect the histological progression of PBC. 28 Treatment with UDCA significantly delayed the progression of liver fibrosis but rarely sustained histological regression, 29 whereas UDCA has been reported to have beneficial effects at different stages of disease before BDL becomes irreversible. 27 These findings may provide a reason why liver fibrosis is a more critical component than BDL in determining long-term prognosis in PBC.
Nevertheless, the present study has several limitations, including absence of clinicopathological or prognostic data and a small sample size. Moreover, the number of events was too small to support a multivariate analysis. With respect to serum γ-GTP levels, we were unable to exclude the possibility of drug-induced liver injury caused by agents other than UDCA. Future prospective studies are required to validate the findings of the present study.
Collectively, a favorable biochemical response after 1 year of UDCA treatment is currently defined as a ≥69% decrease in γ-GTP levels, a single biochemical parameter, which may have utility as a surrogate marker to identify the individuals in whom a favorable biochemical response to UDCA was achieved and in whom UDCA monotherapy should be continued. The presence of portal-portalbridging fibrosis at baseline could serve as a poor prognostic sign and a surrogate end-point for evaluating the clinical benefit of a treatment. Figure 5 Kaplan-Meier estimates of survival in 106 patients with primary biliary cirrhosis (PBC) including a total of 17 patients who died during the study period. Of these 17 patients, 10 died from hepatic disease according to Scheuer and Nakanuma histological stage. The remaining 7 patients, who died of non-hepatic disease, were censored. (a) Survival rate of patients with PBC in Scheuer stage 1 was significantly higher than that of those in Scheuer stages 3 or 4 (P < 0.05 and P < 0.01, respectively). (b) Survival rate of patients with PBC in Nakanuma stage 1 was significantly higher than that of those in Nakanuma stage 4 (P < 0.01). (c) Patients with a Nakanuma fibrosis score of 0 had better prognosis than those with a Nakanuma fibrosis score of 2 or 3 (P < 0.001). (d) Patients with a Nakanuma bile duct loss (BDL) score of 0 had better prognosis than those with a Nakanuma bile duct score of 3 (P < 0.05).
